Highlights AIM Vaccine Co., Ltd.

Equities

6660

CNE100005KF2

Market Closed - Hong Kong S.E. Other stock markets 01:39:05 07/06/2024 pm IST			5-day change	1st Jan Change
6.89 ^HKD	-2.68%		+4.39%	-12.23%

05/06	AIM Vaccine Submits Pre-Applications for Clinical Trials for MRNA RSV, Shingles Vaccines	MT
04/06	Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus And Shingles/Herpes Zoster of Aim Vaccine	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus And Shingles/Herpes Zoster of Aim Vaccine	04/06	CI
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	28/03	MT
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	28/03	MT
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine	28/03	CI
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)	28/03	CI
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine	26/03	CI
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%	04/03	MT
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine	04/03	CI
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	04/03	CI
Aim Vaccine Co., Ltd. Announces Completion of the Layout of Iterative Rabies Vaccine Products and Fully Advancing the Research and Development of the Product Series	04/03	CI
AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine	04/03	CI
Aim Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine	04/03	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine	01/03	CI
Chairman Increases Stake in AIM Vaccine	10/01	MT
AIM Vaccine Chairman Boosts Stake in Firm	02/01	MT
Haoxiangni Health Food, Yankershop Food to Buy Minority Stakes in Local Snack Maker Lingshi Henmang	20/12	MT
AIM Vaccine Chairman Boost Shareholding	07/12	MT
AIM Vaccine Chairman Boosts Shareholding	30/11	MT
AIM Vaccine Launches Share Buyback Plan	24/23/24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AIM Vaccine Co., Ltd.

Equities

6660

CNE100005KF2

Highlights

Filters